On Thursday, Gilead Sciences, Inc. (NASDAQ:GILD) reported second-quarter revenue of $6.95 billion, beating the consensus of $6.72 billion. Sales increased 5% year over year primarily due to higher product sales in HIV, Liver Disease, and Oncology. Product sales excluding Veklury increased 6% year-over-year to $6.7 billion. Adjusted EPS was $2.01, up from $1.34 a year ago, beating the consensus of $1.60, primarily driven by lower operating expenses and higher revenues. Also Read: Gilead’s $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price. HIV product sales increased 3% to $4.7 billion in the second quarter of 2024, primarily driven by higher demand across treatment and prevention. Lower average realized price due to channel mix partially offset this. Biktarvy sales increased 8% to $3.2 billion in the second quarter, driven by higher demand. Descovy sales decreased 6% to $485 million in the second quarter due to lower ...